Home › Funds › Rhenman & Partners Asset Management AB › ERAS
Rhenman & Partners Asset Management AB position in ERAS
ERASCA INC · Health Care
Rhenman & Partners Asset Management AB reported holding 608,750 shares of ERAS (ERASCA INC) in its Q3 2026 13F filing — a position valued at US$8.9M, representing 0.99% of its reported portfolio and ranking #41 among its reported holdings. Rhenman & Partners Asset Management AB has disclosed ERAS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Rhenman & Partners Asset Management AB's ERAS position evolved
Rhenman & Partners Asset Management AB first disclosed a stake in ERAS in Q2 2026 at 349,000 shares (US$6.4M). The position peaked in Q3 2026 at 608,750 shares, worth US$8.9M. Across 2 filings, Rhenman & Partners Asset Management AB increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 608,750 shares valued at US$8.9M — an increase of 259,750 shares quarter over quarter.. Notable position changes include a 74% increase in Q3 2026 (shares rose 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 349.00K | $6.39M | New |
| Q3 2026 | 608.75K | $8.92M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 75 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$457.5M), RTW INVESTMENTS, LP (US$328.8M), Venrock Adviser, LLC (US$327.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 24.98M sh · $457.55M · Q2 2026
- RTW INVESTMENTS, LP 17.95M sh · $328.78M · Q2 2026
- Venrock Adviser, LLC 17.89M sh · $327.78M · Q2 2026
- Logos Global Management LP 12.15M sh · $222.59M · Q2 2026
- Siren, L.L.C. 13.20M sh · $193.48M · Q3 2026
- Paradigm Biocapital Advisors LP 9.55M sh · $174.96M · Q2 2026
- ARCH Venture Management, LLC 7.09M sh · $129.92M · Q2 2026
- Cormorant Asset Management, LP 6.00M sh · $109.92M · Q2 2026
- Affinity Asset Advisors, LLC 5.25M sh · $96.18M · Q2 2026
- Vivo Capital, LLC 4.02M sh · $58.94M · Q3 2026
- a16z Capital Management, L.L.C. 2.86M sh · $52.44M · Q2 2026
- Soleus Capital Management, L.P. 2.70M sh · $49.46M · Q2 2026
More on Rhenman & Partners Asset Management AB
FAQ
How long has Rhenman & Partners Asset Management AB held ERAS?
Rhenman & Partners Asset Management AB has disclosed ERAS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Rhenman & Partners Asset Management AB's current position in ERAS?
As of Q3 2026, Rhenman & Partners Asset Management AB holds 608.75K shares of ERAS (ERASCA INC), valued at $8.92M, representing 0.99% of its reported portfolio and ranking #41.
Has Rhenman & Partners Asset Management AB been buying or selling ERAS?
In the latest 13F filing (Q3 2026), Rhenman & Partners Asset Management AB increased its position in ERAS. The position peaked in Q3 2026 at 608.75K shares.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 75 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.